ELAN Stock Chart & Stats
$380.00
$0.00(0.00%)
At close: 4:00 PM EDT
$380.00
$0.00(0.00%)
Day’s Range― - ―
52-Week Range$252.01 - $399.50
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
$229.26B
Enterprise Value$15.67K
Total Cash (Recent Filing)$428.00M
Total Debt (Recent Filing)$3.99B
Price to Earnings (P/E)―
Beta-0.02
Next Earnings
Aug 05, 2026EPS Estimate
4.67Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.50
Shares Outstanding499,449,600
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio0.28
Price to Book (P/B)1.72
Price to Sales (P/S)2.38
P/FCF Ratio39.55
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$523.01Price Target Upside37.64% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering11
EPS Forecast (FY)18.58
Revenue Forecast (FY)$88.41B
Bulls Say, Bears Say
Bulls Say
Product Innovation & Market ShareStrong adoption of new franchises (Zenrelia, Credelio Quattro, Adtab) demonstrates durable commercial moat: high reorder rates, broad clinic penetration and international share gains support repeatable revenue, pricing leverage with vets, and structural market-share expansion over coming years.
Positive Free Cash FlowConsistent positive operating and free cash flow despite accounting losses indicates strong cash conversion and resilience. This durable cash generation supports deleveraging, capex for capacity, and disciplined M&A without relying on equity issuance, improving long-term financial flexibility.
Improving Balance Sheet & Deleveraging PathBalance-sheet metrics show meaningful improvement from peak leverage: sizable equity base and a clear management plan to reduce net leverage provide a durable cushion for investment and risk absorption, lowering refinancing risk and enabling strategic options over the next 2–3 years.
Bears Say
Ongoing Net Losses & Uneven ProfitabilityRepeated net losses and negative return on equity signal that accounting profitability remains inconsistent. Over time this can limit ability to fund dividends or buybacks, constrain strategic flexibility, and require continued reliance on free cash flow and disciplined cost programs to translate revenue gains into sustained net income.
Gross Margin Pressure And Launch CostsNear-term gross margin compression from inflation, inventory cost flow-through and product mix, combined with higher launch and R&D spend, can structurally depress profitability. If cost inflation or promotional intensity persists, margin recovery may be delayed and limit sustainable EBITDA expansion.
Regulatory & Capacity Execution Risk (Zenrelia)Regulatory delays and significant capacity scaling requirements for a core blockbuster create execution risk: U.S. label expansions may be postponed, incremental studies and capex increase costs, and supply constraints could cap near-term volume growth, weakening durable revenue momentum.
Elanco Animal Health News
ELAN FAQ
What was Elanco Animal Health’s price range in the past 12 months?
Elanco Animal Health lowest stock price was $252.01 and its highest was $399.50 in the past 12 months.
What is Elanco Animal Health’s market cap?
Elanco Animal Health’s market cap is $229.26B.
When is Elanco Animal Health’s upcoming earnings report date?
Elanco Animal Health’s upcoming earnings report date is Aug 05, 2026 which is in 4 days.
How were Elanco Animal Health’s earnings last quarter?
Elanco Animal Health released its earnings results on May 06, 2026. The company reported $6.939 earnings per share for the quarter, beating the consensus estimate of $6.002 by $0.937.
Is Elanco Animal Health overvalued?
According to Wall Street analysts Elanco Animal Health’s price is currently Undervalued.
Does Elanco Animal Health pay dividends?
Elanco Animal Health does not currently pay dividends.
What is Elanco Animal Health’s EPS estimate?
Elanco Animal Health’s EPS estimate is 4.67.
How many shares outstanding does Elanco Animal Health have?
Elanco Animal Health has 499,449,600 shares outstanding.
What happened to Elanco Animal Health’s price movement after its last earnings report?
Elanco Animal Health reported an EPS of $6.939 in its last earnings report, beating expectations of $6.002. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Elanco Animal Health?
Currently, no hedge funds are holding shares in MX:ELAN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Elanco Animal Health Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$523.01 (37.64% Upside)
$523.01 (37.64% Upside)
Blogger Sentiment
Bullish
MX:ELAN Sentiment 80%
Sector Average ―
Sector Average ―
Insider Transactions
Bought Shares
Worth $199.8K over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
69.57%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
2.17%
Trailing 12-Months
Company Description
Elanco Animal Health
Elanco Animal Health, a firm dedicated to animal well-being, creates, produces, and commercializes a diverse array of solutions for both companion animals and livestock. For household pets, the company provides preventative health solutions, including parasiticides and vaccinations, designed to guard against common ailments like worms, fleas, and ticks, with notable brands such as Seresto, Advantage, Advantix, and Advocate. Additionally, Elanco supplies therapeutic treatments for canine and feline conditions including pain, osteoarthritis, ear infections, cardiovascular issues, and dermatological problems, marketed under labels like Galliprant and Claro. Its portfolio for agricultural animals encompasses vaccines, antibiotics, parasiticides, and other essential products for poultry and aquaculture farming. This segment also features nutritional supplements such as enzymes, probiotics, and prebiotics to support animal health and growth. Furthermore, the company offers a comprehensive suite of products for ruminant and swine operations, comprising vaccines, antibiotics, implants, and parasiticides, often recognized by brands like Rumensin and Baytril. Elanco distributes its offerings through various channels, including independent distributors, veterinary clinics, and a broad spectrum of farm animal producers, from cattle and dairy farms to pig, poultry, and aquaculture enterprises. Established in 1954, Elanco Animal Health Incorporated maintains its corporate headquarters in Greenfield, Indiana.
ELAN Company Deck
ELAN Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presented a materially positive picture: strong Q1 performance (10% organic growth, $1.371B revenue), major share gains and product momentum (Zenrelia, Credelio Quattro and Adtab), raised full-year guidance, meaningful EBITDA and EPS improvement, and a credible path to deleveraging supported by Elanco Ascend productivity plans and disciplined M&A. Near-term headwinds include a 40-basis-point gross margin decline in Q1, higher operating investments, regulatory work required for Zenrelia's U.S. label expansion, capacity scaling needs, and external timing effects (China/Middle East) and competitive risks that could temper near-term upside. Overall, the positives (outperformance, raised guidance, blockbuster product traction and clear balance-sheet focus) outweigh the manageable operational and timing risks discussed.View all MX:ELAN earnings summariesELAN Stock 12 Month Forecast
Average Price Target
$523.01
▲(37.64% Upside)